ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements
Sanofi Consumer Healthcare India Ltd reported revenue from operations of ₹235.7 Cr (+6.7% YoY) and net profit of ₹68.8 Cr (+13.3% YoY) for Q1 FY27.
Sanofi Consumer Healthcare India Limited will hold a board meeting on 28th July 2026 to consider and approve its unaudited financial results.
The company filed its quarterly shareholding pattern for the period ending June 30, 2026, detailing the distribution of equity among promoter and public shareholders.
Sanofi Consumer Healthcare India appointed PwC as Statutory Auditor. The term spans five consecutive years until the 8th AGM in 2031.
Sanofi Consumer Healthcare India held its 3rd AGM. The meeting concluded with the transaction of various ordinary and special business items.
Sanofi Consumer Healthcare India Limited submitted its Business Responsibility and Sustainability Report for FY 2025. The report details the company's environmental, social, and governance performance.
Sanofi Consumer Healthcare will hold its 3rd AGM on June 26, 2026. Key agenda items include dividend declaration and appointment of statutory auditors.
Sanofi Consumer Healthcare India Limited has dispatched its Annual Report for FY2025. The company's 3rd Annual General Meeting is scheduled for June 26, 2026.
Sanofi Consumer Healthcare will hold its 3rd AGM on June 26, 2026. The record date for final dividend eligibility is set for June 19, 2026.
Sanofi Consumer Healthcare India appointed Price Waterhouse & Co as Statutory Auditors for a five-year term. The appointment strengthens the company's financial oversight and audit framework.
Sanofi Consumer Healthcare India appointed Price Waterhouse & Co as Statutory Auditors for a five-year term starting 2026. This follows the resignation of the previous auditors.
Nippon India Mutual Fund acquired 30,000 shares of Sanofi Consumer Healthcare India Limited through open market transactions. This increased their total holding from 4.9155% to 5.0458%, crossing the 5% regulatory disclosure threshold. The acquisitions occurred between June 14, 2024, and April 29, 2026.
Sanofi Consumer Healthcare India Limited announced the resignation of its statutory auditor, M/s. Kalyaniwalla & Mistry LLP, effective April 30, 2026. The auditor cited commercial unviability after the company declined a proposed fee increase for FY 2026. The resignation does not involve any concerns regarding audit evidence or other undisclosed circumstances.
Sanofi Consumer Healthcare India Limited reported Q1'26 revenue of ₹229.20 Crore, a 33% year-on-year growth. Net profit reached ₹67.80 Crore, up 36%. Domestic sales grew 15.5%, supported by product relaunches, while exports surged 144% from a low base. The results demonstrate sustained growth momentum following its demerger from Sanofi India Limited.
Sanofi Consumer Healthcare India Ltd reported revenue from operations of ₹229.2 Cr (+32.8% YoY) and net profit of ₹67.8 Cr (+35.6% YoY) for Q4 FY26.
Sanofi Consumer Healthcare India Ltd reported a total income of ₹234.8 Crore for the quarter ended March 31, 2026. The company achieved a net profit of ₹67.8 Crore for the same period. This filing marks the disclosure of the unaudited standalone financial performance following the Board of Directors' approval.
Sanofi Consumer Healthcare India Limited announced the results of its postal ballot held on April 22, 2026. Shareholders approved all four ordinary resolutions, including material related party transactions and executive remuneration amendments, with over 99.9% majority. The scrutinizer confirmed the resolutions were passed with the requisite majority.